Misogi Labs develops advanced machine learning models for complex data analysis and predictive modeling. The company specializes in creating custom deep learning architectures tailored for enterprise-scale data processing challenges. Their solutions enable organizations to derive actionable insights from large, unstructured datasets efficiently.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery is often hampered by late-stage failures due to unfavorable Absorption, Distribution, Metabolism, and Excretion/Pharmacokinetic (ADME/PK) properties of small molecule candidates. Traditional methods for assessing these properties rely heavily on experimental testing, including animal studies, which are time-consuming, expensive, and may not accurately predict human responses.
Solution
Misogi Labs offers an AI-driven platform that predicts ADME/PK properties of small molecules using a physics-infused AI engine. This platform enables researchers to virtually test and optimize molecular candidates early in the drug discovery process, reducing the reliance on experimental methods and animal testing. By integrating with physiological models, the AI-drug hunter predicts pharmacokinetic profiles in humans. The platform acts as a strategic coordinator, bringing together insights from medicinal chemists, pharmacologists, and computational scientists to guide multi-parameter optimization.
Target Audience
The primary target audience includes pharmaceutical R&D teams, medicinal chemists, pharmacologists, and computational scientists involved in small molecule drug discovery and optimization.
Features
- Physics-infused AI engine for predicting ADME/PK properties.
- Miso-5D: A large model pre-trained on multi-modal, physics-driven data, including 4D molecular conformations and quantum mechanical (QM) properties.
- Generative AI to design new experiments and guide molecular optimization.
- Seamless integration through an intuitive interface, providing access to real-time predictions and goal-directed molecular editing.
- Integration with physiological models to predict pharmacokinetic profiles in humans.